TEVA vs. TMO: Teva Pharmaceutical vs. Thermo Fisher Scientific Stock Comparison

Company Profile

Teva Pharmaceutical (TEVA) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but TEVA is classified in Pharmaceuticals while TMO is classified in Life Sciences Tools & Services.

Thermo Fisher Scientific (TMO) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Teva Pharmaceutical (TEVA) at 6.65% and Thermo Fisher Scientific (TMO) at 13.38% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Thermo Fisher Scientific (TMO) at 14.94% retains a top-quartile share of revenue as profit, ahead of Teva Pharmaceutical (TEVA) at 2.94%, which keeps about the industry-typical share.

Both Teva Pharmaceutical (TEVA) at 27.40% and Thermo Fisher Scientific (TMO) at 20.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Teva Pharmaceutical (TEVA) at 4.31% and Thermo Fisher Scientific (TMO) at 3.91% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Thermo Fisher Scientific (TMO) reports EPS growth of 7.32%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Teva Pharmaceutical (TEVA) at 0.95 and Thermo Fisher Scientific (TMO) at 1.81 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but TEVA is more stretched: Thermo Fisher Scientific (TMO) at 0.75 sits in the higher-leverage quartile and Teva Pharmaceutical (TEVA) at 2.13 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.

Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.

Dividend Metrics

Valuation

Thermo Fisher Scientific (TMO) at 36.64 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Thermo Fisher Scientific (TMO) at 5.44 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Teva Pharmaceutical (TEVA) at 6.23 and Thermo Fisher Scientific (TMO) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics